Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes
- 8 July 1987
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 907 (2), 163-174
- https://doi.org/10.1016/0304-419x(87)90004-7
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- ‘Supernatural’ killer cellsImmunology Today, 1985
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- DBA/2-like minor histocompatibility antigens on a BALB/c lymphoma. A balb/c anti-DBA/2 serum which lyses the tumor and blocks balb/c anti-tumor and anti-DBA/2 effectorsInternational Journal of Cancer, 1985
- Allostimulation-induced tumor cytotoxic cells: from mouse to manImmunology Today, 1985
- Passive adoptive immunotherapy of low‐immunogenic BALB/C lymphoma by syngeneic alloimmune T lymphocytesInternational Journal of Cancer, 1984
- Primary but not metastatic human melanomas expressing dr antigens stimulate autologous lymphocytesInternational Journal of Cancer, 1984
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Cross-reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h-2 and non-h-2 alloimmune balb/c miceInternational Journal of Cancer, 1982
- Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cellsNature, 1982
- Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor.The Journal of Experimental Medicine, 1982